title: Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma.
abstract: In the present study, we used a polymerase chain reaction-based (PCR-based) strategy to retrospectively analyze the presence of residual myeloma cells in serial posttransplant bone marrow samples obtained from 13 patients in remission after allogeneic hemopoietic stem cell transplantation (allo SCT). For this purpose, patient-specific primers were generated from complementarity determining regions 2 and 3 of the rearranged IgH gene. The level of sensitivity of the PCR-based assay ranged from 1 in 10(5) to 1 in 10(6) normal marrow cells. Following transplantation, 9 of 12 patients who attained stringently defined complete remission (CR) remained persistently PCR(-) for a median of 36 months, and 4 of the patients remained PCR(-) up to the latest analysis, which was performed at 48, 72, 72, and 120 months, respectively, after allo SCT. None of the patients in the PCR(-) subgroup experienced a disease relapse, and only 1 of 4 PCR(+) patients experienced a relapse. It is concluded that allo SCT has the potential ability to induce sustained serological and molecular CR in selected patients with multiple myeloma.
authors.affiliation: Institute of Hematology and Medical Oncology "Seràgnoli," University of Bologna, Bologna, Italy. mcavo@med.unibo.it
authors.forename: M
authors.initials: M
authors.lastname: Cavo
authors.forename: C
authors.initials: C
authors.lastname: Terragna
authors.forename: G
authors.initials: G
authors.lastname: Martinelli
authors.forename: S
authors.initials: S
authors.lastname: Ronconi
authors.forename: E
authors.initials: E
authors.lastname: Zamagni
authors.forename: P
authors.initials: P
authors.lastname: Tosi
authors.forename: R M
authors.initials: RM
authors.lastname: Lemoli
authors.forename: M
authors.initials: M
authors.lastname: Benni
authors.forename: G
authors.initials: G
authors.lastname: Pagliani
authors.forename: G
authors.initials: G
authors.lastname: Bandini
authors.forename: S
authors.initials: S
authors.lastname: Tura
mesh_terms: D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D009101:Multiple Myeloma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018365:Neoplasm, Residual / Q000401:mortality / Q000473:pathology*; D009679:Nuclear Family; D016133:Polymerase Chain Reaction / Q000379:methods; D015996:Survival Rate; D014184:Transplantation, Homologous; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D007166:Immunosuppressive Agents; D001613:beta 2-Microglobulin